RecruitingNCT07785154

A Registry-study of ELZONRIS in Participants With BPDCN

Post-Authorisation Registry of ELZONRIS (Tagraxofusp) in Patients With Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)

Sponsor

Stemline Therapeutics, Inc.

Enrollment

80 participants

Start Date

Jun 26, 2024

Study Type

OBSERVATIONAL

Conditions

Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)

Summary

The main goal of this registry study is to investigate the effectiveness and safety of tagraxofusp in the treatment of adult participants with BPDCN in the real-world clinical practice setting.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called Tagraxofusp for people with blastic plasmacytoid dendritic cell neoplasm (bpdcn). The study is currently recruiting participants at 41 locations. People eligible for this study include aged 18 Years and older.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGTagraxofusp

No study medication will be provided by the sponsor during this study.

Locations(41)

Medical University Innsbruck

Innsbruck, Austria

Ordensklinikum Linz Krankenhaus der Elisabethinen Linz

Linz, Austria

Salzburg Cancer Research Institute (SCRI)

Salzburg, Austria

Medizinische Universitat Wien, Department for Internal Medicine I, Division of Hematology and Haemostaseology

Vienna, Austria

Universitätsklinikum Augsburg

Augsburg, Germany

Hospital Bielefeld

Bielefeld, Germany

Klinikum Chemnitz

Chemnitz, Germany

University Clinic of Frankfurt

Frankfurt, Germany

University clinic of Freiburg

Freiburg im Breisgau, Germany

Universitätsmedizin Halle

Halle, Germany

Asklepios Hamburg

Hamburg, Germany

University Medical Center Hamburg - Eppendorf

Hamburg, Germany

Community Hospital Kiel

Kiel, Germany

Universitätsklinikum Leipzig Klinik und Poliklinik für Hämatologie, Zelltherapie und Hämostaseologie

Leipzig, Germany

Universitätsklinikum Schleswig-Holstein

Lübeck, Germany

Technical University of Munich

Munich, Germany

Oldenburgh

Oldenburg, Germany

Medizinische Klinik Universitat Tübingen

Tübingen, Germany

AON SS Antonio e Biagio e C Arrigo Alessandria SOC Ematologia

Alessandria, Italy

AOU di Bologna - Policlinico S. Orsola-Malpighi - UOC Ematologia

Bologna, Italy

CTC U.O di Ematologia con Trapianto di Midollo Osseo - Catania

Catania, Italy

ASO S. Croce e Carle - Cuneo - SC Ematologia

Cuneo, Italy

AOU Arcispedale Sant'Anna Cona (FE) - UOC Ematologia e Fisiopatologia della Coagulazione

Ferrara, Italy

AOU Careggi - Firenze - SOD Ematologia

Florence, Italy

IRCCS AOU San Martino - Genova - UO Clinica Ematologica

Genova, Italy

UO Ematologia e Terapie Cellulari, IRCCS Ospedale Policlinico San Martino - Genoa

Genova, Italy

Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico - Milano - Ematologia

Milan, Italy

SC Ematologia - ASST Grande Ospedale Metropolitano Niguarda

Milan, Italy

AOU Federico II - UOC Ematologia e Trapianti di Midollo

Naples, Italy

AOU di Padova - UO Ematologia

Padova, Italy

AO Ospedali Riuniti Villa Sofia Cervello Palermo - UO Ematologia con UTMO

Palermo, Italy

Fondazione IRCCS Policlinico San Matteo Pavia UO Ematologia

Pavia, Italy

AO di Perugia, Ospedale S. Maria della Misericordia - Ematologia E Trapianto Midollo Osseo

Perugia, Italy

ASL Pescara - Presidio Ospedaliero "Spirito Santo" - UOC Ematologia Clinica

Pescara, Italy

AOU Policlinico Tor Vergata - Roma - Ematologia

Roma, Italy

Fondazione Policlinico Universitario Agostino Gemelli IRCCS - Roma - Area Ematologica

Roma, Italy

AOU 'San Giovanni di Dio e Ruggi d'Aragona' Salerno - UOC Ematologia

Salerno, Italy

AOU Città della Salute e della Scienza - Ospedale S. G. Battista Molinette - Torino - SC Ematologia

Torino, Italy

ASUI di Udine - Presidio Ospedaliero "Santa Maria della Misericordia" - Clinica Ematologica

Udine, Italy

Insel Gruppe AG, Bern University Hospital

Bern, Switzerland

Luzerner Kantonsspital

Lucerne, Switzerland

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07785154

Related Trials

A Non-interventional Study of Participants With BPDCN Treated With Chemotherapy

NCT07785180

Phase II Study Evaluating the Efficacy and Safety of the Combination of Tagraxofusp and Venetoclax in Treatment-naive Blastic Plasmacytoid Dendritic Cell Neoplasm Patients

NCT0700705234 locations

Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) International Registry

NCT0543097122 locations

CART123 T Cells in Relapsed or Refractory CD123+ Hematologic Malignancies: A Dose Escalation Phase I Trial

NCT067658761 location

Safety and Efficacy of CD123-targeted CAR-NK for Relapsed/Refractory Acute Myeloid Leukemia or Blastic Plasmacytoid Dendritic Cell Neoplasm

NCT060064031 location